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https://en.wikipedia.org/wiki/Portal_hypertension 
Portal 
hypertension (PH) is a 
clinical syndrome 
defined by a 
pathological increase in 
portal venous pressure 
(PVP)  
INTRODUCTION 
• PH is elevated pressure in the portal vein 
• It is caused most often by cirrhosis (in developed countries), 
schistosomiasis (in endemic areas), or hepatic vascular 
abnormalities 
• Consequences include esophageal varices and portosystemic 
encephalopathy 
• Diagnosis is based on clinical criteria, often in conjunction 
with imaging tests and endoscopy 
• Treatment involves prevention of GI bleeding with 
endoscopy, drugs, or both and sometimes with portacaval 
shunting or liver transplantation 
http://www.msdmanuals.com/professional/hepatic-and-biliary-disorders/approach-to-the-patient-with-liver-disease/portal-
hypertension 
DEFINITION 
•PH is defined as a portal vein pressure greater 
than 10mmHg (250mm water column) 
•Normal portal venous pressure is 5–10mmHg, 
which is sufficient to maintain a portal flow ( 
13-24cm water column) 
•Pressure in the portal vein of patients with PH 
exceeds 25cm water column 
HISTORY 
• Hallion and Francois-Frank attempted the first 
PV pressure measurement in 1896 by 
inserting a cannula into the mesenteric vein of 
a dog and connecting it to a water manometer 
• Direct measurement of portal pressure is 
invasive, inconvenient, and clinically 
impractical 
 
Hallion L, Francois-Frank CA. Recherches experimentales executees a l’aide d’um novel appareil volumetrique sur l’innervation vaso-motrice de l’intestin. Arch Physiol Norm Pathol 1896;8:493- 508. 
HISTORY 
• In 1951, Myers and Taylor first described the 
measurement of wedged hepatic venous 
pressure (WHVP), which reflected sinusoidal 
pressure, an indirect measure of PV pressure 
• Since then, the measurement of WHVP has 
been proven to be safe and closely correlated 
with the directly measured PVP  
• Now widely used measurement of hepatic 
venous pressure gradient 
 
Myers JD, Taylor WJ. An estimation of portal venous pressure by occlusive catheterization of a hepatic venule. J Clin Invest 1951;30:662-
3. 
 ANATOMY 
• The portal venous system 
drains all blood from the 
abdominal GI tract, spleen, 
pancreas, and gallbladder back 
to the heart through the liver 
• At the porta hepatis it divides 
into the right and left 
branches, which are 
segmentally distributed 
intrahepatically 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
ANATOMIC CHARACTERISTICS OF 
PORTAL VENOUS SYSTEM 
• The liver is a unique organ in that it has a dual 
blood supply: portal venous and hepatic 
arterial 
• The PV is formed from the confluence of the 
superior mesenteric and splenic veins behind 
the neck of the pancreas and is 6 to 8 cm in 
length 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
ANATOMIC CHARACTERISTICS OF 
PORTAL VENOUS SYSTEM 
• The tributaries of the PV connect with systemic 
venous system at the following sites:  
• with the azygos vein and hemiazygos vein by coronary 
vein and esophageal plexus 
• with middle and inferior haemorrhoid veins by inferior 
mesenteric vein and superior haemorrhoid vein 
• with superior and inferior epigastric vein by 
obliterated umbilical vein and paraumbilical vein 
• PV, SMV and IMV connect with IVC by retroperitoneal 
vein 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
 ANATOMY 
https://herbsforhealthandwellbeing.wordpress.com/tag/anatomy-of-the-liver/ 
 ANATOMY 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
● The internal structure of the liver is 
made of around 100,000 small 
hexagonal functional units known as 
lobules 
● Each lobule consists of a central vein 
surrounded by 6 hepatic portal veins 
and 6 hepatic arteries 
● These blood vessels are connected 
by many capillary-like tubes called 
sinusoids, which extend from the 
portal veins and arteries to meet the 
central vein like spokes on a wheel 
● Each sinusoid passes through liver 
tissue containing 2 main cell types: 
Kupffer cells and hepatocytes 
ETIOLOGY 
• Causes of PH may be divided into diseases 
within the liver and diseases of the blood 
vessels outside the liver 
• With the exception of the rare splanchnic 
arteriovenous fistulas, all the conditions cause 
PH by producing obstruction to portal blood 
flow  
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
ETIOLOGY 
• The two most common causes of PH worldwide 
are cirrhosis and hepatic schistosomiasis  
• In Western countries, PH is typically the result of 
cirrhosis, with noncirrhotic PH accounting for less 
than 10 percent of cases 
• In other parts of the world, noncirrhotic PH due to 
causes such as schistosomiasis and PV thrombosis 
are the leading causes of PH 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
 CLASSIFICATION OF PH 
• There are two separate and sometimes overlapping 
classification systems for the causes of PH, using either 
the liver or the hepatic sinusoid as the reference point 
• The former classifies conditions into prehepatic, 
intrahepatic and posthepatic causes, while the latter 
divides conditions into presinusoidal, sinusoidal and 
postsinusoidal causes 
• The clinical usefulness of this classification is in 
separating patients who have normal hepatocellular 
function from those who have hepatocellular damage 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
  CLASSIFICATION OF PH 
http://www.tankonyvtar.hu/en/tartalom/tamop412A/2011-0095_fogaszat_angol/ch01s29.html 
CLASSIFICATION OF PH 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
FORMS AND CAUSES OF 
PREHEPATIC PH 
 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
CAUSES OF PRESINUSOIDAL BLOCK IN 
INTRAHEPATIC  PH 
• Congenital 
1. Rendu-Osler-Weber disease 
2. Gaucher’s disease 
3. Cholangiodysplasia or congenital liver 
fibrosis (microcystic liver), congenital 
polycystic disease 
• Acquired 
1. Thrombosis of the portal venous 
branches  
2. Aneurysmal dilatation of the PV  
3. Primary biliary cholangitis, primary 
sclerosing cholangitis 
4. Sclerosing granulomas: 
schistosomiasis,  sarcoidosis, 
tuberculosis  
5. Myeloproliferative syndromes  
 
6. Toxically induced hepatoportal 
sclerosis/periportal fibrosis: arsenic,  vinyl 
chloride monomers,  insecticides (particularly 
with copper sulphate), cytostatics 
(methotrexate, 6-mercaptopurine), cyanamide 
7. Collagenoses  
8. Haemoblastoses (e.g. mastocytosis) 
9. Lymphoblastoses 
10. Wilson’s disease 
11. Haemochromatosis 
12. Malignant diseases 
13. Liver adenoma 
14. Nodular regenerative hyperplasia  
15. Partial nodular transformation  
16. Idiopathic (non-cirrhotic) presinusoidal block 
 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
 PRESINUSOIDAL BLOCK IN INTRAHEPATIC  
PH 
 
http://eaun17.uroweb.org/schistosomiasis-a-deadly-neglected-tropical-disease/ 
 PRESINUSOIDAL BLOCK IN INTRAHEPATIC  PH 
SCHISTOSOMIASIS 
 
http://eaun17.uroweb.org/schistosomiasis-a-deadly-neglected-tropical-disease/ 
CAUSES OF A SINUSOIDAL BLOCK IN 
INTRAHEPATIC PH 
1. Storage of substances 
 fatty liver 
 acute fatty liver in pregnancy 
 amyloidosis  
 glycogenosis type III  
 Gaucher’s disease 
 Niemann-Pick disease  
 α1-antitrypsin deficiency 
2. Hepatotoxins 
 alcoholic hepatitis 
 vitamin A  
 vinyl chloride, methotrexate 
 
3. Severe parenchymal loss 
 acute viral hepatitis  
 acute liver failure  
 malaria 
4. Peliosis hepatitis 
5. Chronic hepatitis  
6. Regenerative nodes in 
cirrhosis 
7. Formation of nodes 
8. Cirrhosis 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
CAUSES OF A POSTSINUSOIDAL BLOCK 
IN INTRAHEPATIC PH 
1. Liver cirrhosis (e.g. Wilson’s disease, haemochromatosis) 
2. Budd-Chiari syndrome 
•  Stuart-Bras syndrome (veno-occlusive disease, radicular form) 
–  pyrrolizidine alkaloids  contraceptives 
–  cytostatic agents  anabolic agents 
–  immunosuppressants  exposure to X-rays 
–  thorotrast 
•  Chiari’s disease (obliterative hepatic endophlebitis, truncal form) 
3. Alcoholic hepatitis 
4. Alcoholic central hyaline sclerosis 
5. Partial nodular transformation of the liver  
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
POSTSINUSOIDAL PH  
• Budd–Chiari syndrome is 
the least common cause of 
PH, but may be reversible if 
identified and treated early 
• It is a congestive 
hepatopathy caused by 
blockage of hepatic veins. 
This syndrome occurs in 
1/100 000 in the general 
population 
• Hypercoagulable state could 
be identified in 75% of the 
patients 
 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147117/ 
CAUSES OF POSTHEPATIC PH 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
PATHOPHYSIOLOGY OF PH 
• The major theories have been the ‘backward’ and 
the ‘forward’ flow theories:  
– backward theory postulates that all consequences of 
PH result from obstruction to portal venous flow 
– forward flow theory postulates that increased inflow 
to the portal venous system (usually because of 
splenomegaly) causes the changes that lead to the 
clinical findings of PH 
• Current evidence indicates that both theories 
contribute to the pathophysiology 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
PATHOPHYSIOLOGY OF PH 
• In the resting state, the PV carries about 75% 
of total hepatic blood flow and provides 1/2 
of the liver's O2 supply 
• The PV is valveless; thus, pressure in the 
portal system depends on the product of 
input from blood flow in the portal vein and 
total hepatic resistance to outflow 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
PATHOPHYSIOLOGY OF PH 
http://www.vacances-voyages.info/listpnum-portal-hypertension.html 
PATHOPHYSIOLOGY OF PH 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
• Splenomegaly with hypersplenism: the spleen 
may be enlarged and may result in the 
secondary hypersplenism including anemia, 
leukopenia (WBC<3000/mm 3 ) and 
thrombocytopenia 
• Ascites develops in association with severe 
hepatocellular damage and is a manifestation 
of hepatic decompensation 
 
ANAMNESIS 
• The main anamnestic details given by the patient 
are related to various targeted questions: 
– existence of a liver disease 
–  existence of extrahepatic diseases 
–  alcohol abuse 
–  medication 
–  consumption of tea containing alkaloids 
–  tarry stools, haematemesis, bleeding tendency, 
thrombophilia 
–  visits to tropical regions (malaria, etc.) 
–  oedema, abdominal pain 
Kuntz E. Hepatology. Textbook and Atlas / E. Kuntz, H. Kuntz. – Heidelberg: Springer, 2008. – 937 p. 
CLINICAL PRESENTATION 
http://www.stepwards.com/?page_id=2014 
• PH is often asymptomatic until complications 
develop 
• Clinical manifestations of PH include: 
o  splenomegaly 
o  abdominal wall collateral vessels 
o   thrombocytopenia 
o  spider angiomata  
o  gynecomastia in a patient with cirrhosis  
o  complications of PH 
CLINICAL PRESENTATION 
http://www.stepwards.com/?page_id=2014 
CLINICAL PRESENTATION 
Caput medusae 
 • Periumbilical veins 
themselves can 
become engorged as 
well 
• Caput medusae are 
engorged epigastric 
veins around the 
umbilicus that are 
seen in the setting of 
PH 
http://www.stepwards.com/?page_id=2014 
CLINICAL PRESENTATION 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
Complications of PH include: 
o Variceal hemorrhage 
o Portal hypertensive gastropathy 
o Spontaneous bacterial peritonitis 
o Hepatorenal syndrome 
o Hepatic hydrothorax 
o Hepatopulmonary syndrome 
o Portopulmonary hypertension 
o Cirrhotic cardiomyopathy 
o Hepatic encephalopathy 
o Ascites 
 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Variceal veins and hemorrhage 
• Variceal veins and 
hemorrhage: patients with 
variceal hemorrhage 
typically present with 
hematemesis and/or melena 
• If the bleeding is severe, 
there may be signs of 
hemodynamic instability 
http://www.ghrnet.org/index.php/joghr/article/view/1121/1219 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Portal hypertensive gastropathy 
• Portal hypertensive gastropathy (PHG): while extremely 
common in patients with PH, is an uncommon cause of 
significant bleeding in these patients 
• When PHG is the sole cause of bleeding, there is diffuse 
mucosal oozing with no other lesions such as varices to 
account for the gastrointestinal bleeding and anemia 
•  The mucosa is friable, and bleeding presumably occurs 
when the ectatic vessels rupture 
• The severity of gastropathy is related to the level of 
portal pressure, the level of hepatic vascular resistance, 
and the degree of reduction in hepatic blood flow  
http://www.ghrnet.org/index.php/joghr/article/view/1121/1219 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Spontaneous bacterial peritonitis 
• Spontaneous bacterial 
peritonitis:  
– fever, abdominal pain 
–  abdominal tenderness 
– altered mental status 
–  Some patients are asymptomatic 
and present with only mild 
laboratory abnormalities 
• The new onset of renal failure 
should prompt an investigation 
for spontaneous bacterial 
peritonitis  
https://www.uptodate.com/contents/portal-hypertension-in-adults 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatorenal syndrome 
• Hepatorenal syndrome 
refers to the development of 
renal impairment in the 
setting of cirrhosis 
• Arterial vasodilatation in the 
splanchnic circulation, which 
is triggered by PH, appears to 
play a central role in the 
hemodynamic changes and 
the decline in renal function 
in hepatorenal syndrome 
 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatorenal syndrome 
• Hepatorenal syndrome (HRS) is a serious complication of liver cirrhosis 
with critically poor prognosis 
• Clinically HRS can be divided into types 1 and 2 
• Type 1 HRS is characterised by a rapid and progressive impairment of 
renal function as defined by a doubling of the initial serum creatinine to a 
level higher than 221 μmol/L in less than 2 weeks; the GFR is usually 
below 20 mL/min; the median survival time is less than 2 weeks and 
practically all patients die within 8–10 weeks after the onset of renal 
failure 
• Type 2 HRS is characterised by a subtler course with initial serum 
creatinine levels less than 221 μmol/L; the main clinical consequence of 
type 2 HRS is diuretic-resistant ascites; patients have a longer median 
survival time of approximately 6 months 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatorenal syndrome 
International Ascites Club’s Diagnostic Criteria of HRS 
Major criteria 
•  Chronic or acute liver disease with advanced hepatic failure and PH 
•  Low GFR: serum creatinine >133 μmol/L or 24h creatinine clearance <40 
mL/min 
•  Absence of shock, ongoing bacterial infection or treatment with nephrotoxic 
drug 
•  Absence of gastrointestinal or renal fluid losses 
•  No sustained improvement in renal function following diuretic withdrawal and 
expansion of plasma volume with 1.5 L of isotonic saline 
•  Proteinuria <0.5 g/d and no ultrasonographic evidence of obstructive uropathy 
or parenchymal renal disease 
Additional criteria 
•  Urine volume <0.5 L/d 
•  Urine sodium <10 mmol/L 
•  Urine osmolality > plasma osmolality 
•  Urine red blood cells <50 high power field 
•      Serum sodium concentration <130 mmol/L 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatic hydrothorax 
• Hepatic hydrothorax is defined as the 
presence of a pleural effusion in a 
patient with cirrhosis and no evidence of 
underlying cardiopulmonary disease 
• It results from the movement of ascitic 
fluid into the pleural space through 
defects in the diaphragm and is usually 
right-sided 
• The negative intrathoracic pressure 
generated during inspiration favors the 
passage of fluid from the peritoneal to 
the pleural space 
• Patients usually present with: 
– shortness of breath 
– cough 
– hypoxemia 
– and/or chest discomfort 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatopulmonary syndrome 
• Hepatopulmonary syndrome is 
defined as the triad of liver disease, 
pulmonary gas exchange 
abnormalities leading to arterial 
deoxygenation, and evidence of 
intrapulmonary vascular dilatations  
• The clinical features are the 
consequences of both hepatic and 
pulmonary dysfunction 
• More than 80 percent of patients 
present with symptoms of liver 
disease; the remainder experience 
dyspnea as their initial symptom 
• Hypoxia is a common finding 
• The prognosis associated with HPS 
is poor 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605324/ 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Portopulmonary hypertension 
• PH-associated pulmonary hypertension 
(portopulmonary hypertension) refers to the 
presence of pulmonary hypertension in patients with 
PH 
• Patients may present with: 
– fatigue 
– dyspnea 
– peripheral edema 
– chest pain 
– syncope 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
THESE COMPLICATIONS 
Cirrhotic cardiomyopathy 
• Cirrhotic cardiomyopathy is defined by 
chronic cardiac dysfunction in the setting of 
cirrhosis 
• It is characterized by decreased contractile 
responsiveness to stress or altered diastolic 
relaxation with electrophysiologic 
abnormalities 
• It is thought to be related to both PH and 
cirrhosis 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
THESE COMPLICATIONS 
Cirrhotic cardiomyopathy 
http://www.sciencedirect.com/science/article/pii/S0914508715001525 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Hepatic encephalopathy 
 
• Hepatic encephalopathy (HE) defined as a disturbance in 
central nervous system function because of hepatic 
insufficiency 
• HE is a reversible state that occurs in patients with liver 
disease or portosystemic shunts 
• HE is a hallmark of deteriorating liver function, and 
patients should be assessed early for liver 
transplantation 
• Suspect in any liver disease patient presenting with 
mental changes 
• HE is usually preceded by precipitating events 
Krige J. Portal hypertension—2. Ascites, encephalopathy, and other conditions / J. Krige, I. Beckingham. // BMJ. – 2001. – №322. – С. 416–418. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
HE (pathogenesis) 
Jalan R. Hepatic encephalopathy and ascites / R. Jalan, P. C. Hayes. // The Lancet. – 1997. – №350. – P. 1309–1315. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
HE (precipitating events) 
• Electrolyte imbalance 
–  Diuretics 
–  Vomiting 
–  Diarrhoea 
• Gastrointestinal bleeding 
–  Oesophageal and gastric 
varices 
–  Gastroduodenal erosions 
• Constipation 
–  Dietary protein overload 
 
• Infection 
–  Spontaneous bacterial 
peritonitis 
–  Urinary 
–  Chest 
• Drugs 
–  Alcohol withdrawal 
–  Benzodiazepines 
–  Barbiturates 
–  Analgesics 
–  Other sedatives 
 
 
Krige J. Portal hypertension—2. Ascites, encephalopathy, and other conditions / J. Krige, I. Beckingham. // BMJ. – 2001. – №322. – С. 416–418. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
HP (clinical presentation) 
• The typical features of HP include: 
–impaired consciousness (drowsiness) 
–monotonous speech 
–flat affect (asterixis) 
–metabolic tremor 
–muscular incoordination 
–impaired handwriting 
–fetor hepaticus 
–upgoing plantar responses 
–hypoactive or hyperactive reflexes 
–decerebrate posturing 
Krige J. Portal hypertension—2. Ascites, encephalopathy, and other conditions / J. Krige, I. Beckingham. // BMJ. – 2001. – №322. – С. 416–418. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
HE (clinical presentation) 
Asterixis 
http://doctorsgates.blogspot.com/2011/02/how-to-test-hepatic-flap-
asterixis.html 
Ask the patient to stretch out their hands in front of them with the hands dorsiflexed at the wrists and 
fingers outstretched and separated. The patient should hold that position for at least 15 seconds. If flap 
is present, the patient's hands will move in jerky, irregular flexion/extension at the wrist and MCP 
joints. The flap is nearly always bilateral. May be subtle and intermittent. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
HE 
THE WEST HAVEN CRITERIA OF ALTERED MENTAL STATE IN HE 
• Stage 0. Lack of detectable changes in personality or behavior. 
Asterixis absent.  
• Stage 1. Trivial lack of awareness. Shortened attention span. 
Impaired addition or subtraction. Hypersomnia, insomnia, or 
inversion of sleep pattern. Euphoria or depression. Asterixis can be 
detected.  
• Stage 2. Lethargy or apathy. Disorientation. Inappropriate behavior. 
Slurred speech. Obvious asterixis.  
• Stage 3. Gross disorientation. Bizarre behavior. Semistupor to 
stupor. Asterixis generally absent.  
• Stage 4. Coma. 
Krige J. Portal hypertension—2. Ascites, encephalopathy, and other conditions / J. Krige, I. Beckingham. // BMJ. – 2001. – №322. – С. 416–418. 
• Ascites can be recognized by the wide protuberance of the 
abdomen with moderate bulging of the abdominal flanks and 
spreading of the navel 
• Examination by percussion produces tympanic intestinal 
resonance in the upper area and typical dullness in the 
flanks 
• Small ascites (about 1 litre) is determined in the knee-elbow 
position, whereby dullness is detected in the lower 
abdominal region 
• The fluctuation wave is an impressive sign: a short hard 
surge of the fluid swell against the palpating hand is virtually 
conclusive  
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Ascites 
 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–
89. 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Ascites (pathophysiology) 
https://www.slideshare.net/gunjanmalviya94/portal-hypertension-44033111 
CLINICAL MANIFESTATIONS ASSOCIATED WITH 
COMPLICATIONS 
Ascites 
 • Patients with ascites typically 
report: 
• progressive abdominal 
distension that may be 
painless or associated with 
abdominal discomfort 
• Also may complain: 
– weight gain 
– shortness of breath 
– early satiety 
– dyspnea resulting from 
fluid accumulation and 
increased abdominal 
pressure 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
DIAGNOSIS 
• Past history of chronic alcoholism, hepatitis, complicated 
biliary disease, or exposure to hepatotoxins should lead one to 
include cirrhosis in the differential diagnosis 
• Nonspecific complaints such as weight loss, malaise, and 
weakness 
• Underlying chronic liver disease on physical examination are 
spider angiomas, palmar erythema, testicular atrophy, and 
gynecomastia 
• A palpable spleen in association with these signs suggests PH 
• Signs of hepatic functional decompensation or advanced PH, 
such as jaundice, ascites, palpation of a firm irregular liver 
edge, dilated abdominal wall veins, impairment of mental 
status or the presence of asterixis (liver flap) 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
Laboratory tests  
Blood test:  
• anemia, leukopenia and 
thrombocytopenia (bleeding, nutritional 
deficiencies, etc) 
• coagulation may also be impaired 
 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
Laboratory tests  
Liver function test will reveal:  
• Serum albumin is often declined (which is a reliable 
index of chronic liver disease) 
• Elevation of hepatocellular enzymes (aspartate 
aminotransferase and alanine aminotransferase)  
• High level of total bilirubin (which are also indicators of 
hepatocellular damages) 
• Hepatitis serology should be obtained in most patients 
with cirrhosis (HBV,HCV) 
•  All newly diagnosed cirrhotic patients should be 
screened for hepatocellular carcinoma by 
determination of α-fetoprotein level 
 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
Laboratory tests  
 
  
 
https://www.aasld.org/sites/default/files/Garcia-Tsao_et_al-2017-Hepatology.pdf 
DIAGNOSIS 
Hepatic venous pressure gradient (HVPG) 
• The HVPG is measured to approximate the gradient in pressure 
between the PV and the inferior vena cava (IVC) 
• It can quantify the degree of PH due to sinusoidal resistance to blood 
flow (the most common cause of PH) 
• A normal HVPG is between 1 and 5 mmHg 
• PH is present if the HVPG is ≥6 mmHg 
• PH typically becomes clinically significant when the HVPG is ≥10 
mmHg, at which point varices may develop 
• Once the HVPG is ≥12 mmHg, patients are at risk for variceal bleeding 
and the development of ascites 
• The portal pressure gradient can also be determined by direct 
measurement of the pressure in the portal vein and IVC, but it is 
associated with a risk of intraperitoneal bleeding, so it is rarely used 
https://www.uptodate.com/contents/portal-hypertension-in-
adults 
DIAGNOSIS 
HVPG Technique 
• The HVPG is calculated by subtracting the free hepatic venous pressure (FHVP, which reflects intra-
abdominal pressure) from the wedged hepatic venous pressure (WHVP, which reflects portal venous 
pressure) 
• These values are obtained by hepatic vein catheterization. The WHVP is typically obtained by balloon 
occlusion of the hepatic vein, though it can also be estimated by wedging the catheter in the end tributaries 
of a hepatic vein. The balloon occlusion technique estimates the pressure from a larger portion of the liver 
than is obtained if the catheter is wedged in an end tributary. 
• After giving the patient light conscious sedation (eg, midazolam), a balloon-tipped catheter is introduced 
through the right jugular vein, often under ultrasound guidance. The catheter is advanced through the right 
atrium into the IVC and then into the right hepatic vein using fluoroscopic guidance. Alternatively, the 
femoral or antecubital veins can be used to for venous access. 
• To obtain the FHVP, the catheter is maintained in the hepatic vein 2 to 4 cm from its take off from the IVC. 
Typically, the difference in pressure between the IVC (measured at the hepatic vein ostium) and hepatic 
vein is ≤1 mmHg. A difference >1 mmHg suggests incorrect placement of the catheter (too deep into the 
hepatic vein). Pressure in the right atrium cannot be used to approximate the FHVP. 
• To obtain the WHVP, the hepatic vein is occluded by inflating the balloon at the tip of the catheter. A small 
amount of contrast dye (5 mL) is injected to confirm that the hepatic vein is occluded. If it is occluded, there 
should be no reflux of the dye above the balloon, and it should not washout via communications with other 
hepatic veins. Veno-venous communications may lead to washout of the contrast. These communications 
are rare in cirrhosis, though they are commonly seen in idiopathic portal hypertension. The pressure should 
not be recorded until a stable value is obtained, which often takes 45 to 60 seconds. 
• Once the FHVP and WHVP are determined, the HVPG is calculated by subtracting the FHVP from the 
WHVP. 
 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
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DIAGNOSIS 
HVPG: Prognostic implications  
Prognostic implications of HVPG thresholds — The risk of developing complications of 
PH and mortality rates increase as HVPG values increase. Various HVPG thresholds have 
been noted to have prognostic significance among patients with cirrhosis: 
●In patients with compensated cirrhosis: 
•HVPG 10 mmHg: Development of gastroesophageal varices, development of 
hepatocellular carcinoma, decompensation after surgery for hepatocellular carcinoma 
•HVPG 12 mmHg: Variceal bleeding 
•HVPG 16 mmHg: First clinical decompensation in patients with varices, mortality 
●In patients with decompensated cirrhosis: 
•HVPG 16 mmHg: Variceal rebleeding, mortality 
•HVPG 20 mmHg (in patients with active variceal hemorrhage): Failure to control active 
variceal hemorrhage, low one-year survival 
•HVPG 22 mmHg: Mortality in patient with alcoholic cirrhosis and acute alcoholic 
hepatitis 
•HVPG 30 mmHg: Spontaneous bacterial peritonitis 
 
https://www.uptodate.com/contents/portal-hypertension-in-
adults 
DIAGNOSIS 
HVPG: Contraindications and limitations 
• Limitation of the HVPG is that the WHVP is a measure of pressure within the 
hepatic sinusoids 
•  As a result, pre-sinusoidal causes of portal hypertension may be associated with a 
normal FHVP, WHVP, and HVPG. 
• HVPG may be normal with post-sinusoidal causes of portal hypertension that 
increase pressure both in the hepatic vein and in the sinusoids. However, in this 
situation, both the FHVP and the WHVP will be abnormal 
• If pre-sinusoidal portal hypertension is suspected and the HVPG is normal, direct 
measurement of the pressure in the PV and IVC can be obtained to determine the 
portal perfusion gradient. Direct measurement is performed using transhepatic or 
transvenous catheterization of the portal vein. 
• A relative contraindication to HVPG measurement is an allergy to iodinated 
contrast. This can be overcome by using carbon dioxide in place of contrast when 
confirming balloon occlusion. In patients with a history of cardiac arrhythmias, care 
should be taken when moving the catheter in the right atrium.  
• Patients with thrombocytopenia or an elevated international normalized ratio 
may require platelets or fresh frozen plasma, respectively, prior to performing an 
HVPG measurement. 
 https://www.uptodate.com/contents/portal-hypertension-in-adults 
DIAGNOSIS 
HVPG: Complications 
• Complications with HVPG measurement are 
uncommon and typically are related to local injury at 
the venous access site  
• Arrhythmias, which are usually transient, may be seen 
as the catheter is moved within the right atrium 
• Associated procedures — other procedures that can 
be performed at the same time as HVPG 
measurement include transjugular liver biopsy, 
measurement of hepatic blood flow and indocyanine 
green clearance, and wedged hepatic retrograde 
portography using carbon dioxide. 
 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
DIAGNOSIS 
Ultrasonography 
• Findings on transabdominal ultrasound with Doppler imaging may support 
a diagnosis of portal hypertension, but lack sensitivity 
• Findings that may be seen in patients with PH include (1): 
– Ascites 
– Splenomegaly 
– Dilation of the splenic vein (>10 mm) 
– Nodular liver 
– Portal flow mean velocity <12 cm/second 
– Inversion of flow in the PV 
– Portosystemic collaterals (patent-paraumbilical vein, splenorenal 
collaterals, dilated left and short gastric veins) 
– Portal vein diameter >13 mm 
– Decreased or no respiratory variation in splenic and superior 
mesenteric vein diameter 
– Portal/splenic/superior mesenteric vein thrombosis 
 https://www.uptodate.com/contents/portal-hypertension-in-
adults 
DIAGNOSIS 
Ultrasonography 
 • Findings that may be seen in patients with PH include (2) : 
–Dilation of the ventricular coronary vein (>6 mm) 
–Reduction of blood flow velocity less than 10 cm/sec 
–Restricted respiratory modulation of the vascular width of up to 3 mm 
(increase on inspiration and decrease on expiration) regarding the PV 
and more particularly the splenic vein and the superior mesenteric 
vein 
–Decrease in width of the lumen by more than 50% on exhalation = 
absence of PH 
–Stasis of the gallbladder and gastric walls 
–Recanalization of the umbilical vein  
–Cavernous transformation of the portal vein 
Krige J. Portal hypertension—2. Ascites, encephalopathy, and other conditions / J. Krige, I. Beckingham. // BMJ. – 2001. – №322. – С. 416–418. 
DIAGNOSIS 
Transient elastography 
• Transient elastography using ultrasound is a noninvasive method 
for detecting hepatic fibrosis 
• Studies are also looking at it as an option for noninvasively 
diagnosing portal hypertension 
• Studies have reported areas under the receiver operating 
characteristic (AUC) curve of 0.77 to 0.99 for transient 
elastography predicting portal hypertension, with variable optimal 
liver stiffness cutoff values (13.6 to 34.9 kPa (Kilopascal)) 
•  It has been suggested that a value <13.6 kPa can be used to rule 
out portal hypertension, whereas a value ≥21.1 kPa can be used 
to rule it in 
• Values between 13.6 and 21.1 kPa are considered to be 
indeterminant 
https://www.uptodate.com/contents/portal-hypertension-in-adults 
DIAGNOSIS 
Liver Biopsy 
• Percutaneous liver biopsy is a useful 
technique for establishing the cause of 
cirrhosis and for assessing activity of the 
liver disease. It should not be done when 
either coagulopathy or moderate ascites 
is present 
• Laparoscopic biopsy reduces the false-
negative rate for diagnosing cirrhosis as 
compared with blind biopsy techniques 
  https://www.slideshare.net/deepak15/portal-hypertension12-
presentation 
DIAGNOSIS 
Ascitic fluid tests 
Required 
• Macroscopic appearance 
(strawcoloured, 
turbid, bloody, chylous) 
• Cell count and differential 
• Albumin 
• Total protein 
• Culture in blood culture 
bottles 
• Gram’s stain 
 
Optional 
• Glucose (for secondary peritonitis) 
• LDH (for secondary peritonitis) 
• Amylase (for pancreatic ascites) 
• AFB smear and turberculosis culture 
• Adenosine deaminase (for 
tuberculosis) 
• Cytology (for malignant ascites) 
• Triglycerides 
• Bilirubin 
• pH, lactate (for bacterial peritonitis) 
 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–89. 
DIAGNOSIS 
Classification of ascites by serum-ascites albumin 
gradient (SAAG) 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–89. 
DIAGNOSIS 
Further 
• Diagnosis of the underlying liver disease  
• Estimation of functional hepatic reserve 
• Definition of portal venous anatomy and 
hepatic hemodynamic evaluation 
• Identification of the site of upper 
gastrointestinal hemorrhage, if present  
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
 Hepatic functional reserve 
https://www.aasld.org/sites/default/files/Garcia-Tsao_et_al-2017-Hepatology.pdf 
DIAGNOSIS 
Special examinations 
Endoscopy 
• In the nonbleeding cases, the manifestation of 
varices may be observed, The risk of the first 
variceal bleed may be predicted from:  
– variceal size 
– «red color signs» 
• In the massive bleeding cases, it is a very useful 
procedure to determine the site and the cause of 
upper gastrointestinal hemorrhage 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
Special examinations 
Computerized Tomography (CT)  
• CT scan is not affected by patients body 
habitus or the presence of bowel gas 
• Compared with ultrasound scan, CT is more 
effective 
• With improvement of spiral CT scan and 3-
dimensional angiographic reconstructive 
techniques, portal vasculature may be 
visualized more accurately 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
DIAGNOSIS 
Special examinations 
Computerized Tomography (CT)  
 
http://www.wikidoc.org/index.php/File:Portal-venous-hypertension-003.jpg 
DIAGNOSIS 
Special examinations 
Barium swallow 
• To demonstrate the presence of esophageal 
varices  
• Esophageal varices may be recognized as a 
tortuous, worm-like appearance of the mucosa on 
a barium swallow 
• The three key variables that are predictive of 
variceal bleeding are Child class, variceal size, and 
the presence and severity of red wale markings 
(indicative of epithelial thickness) 
https://www.slideshare.net/deepak15/portal-hypertension12-presentation 
TREATMENT 
• Treatment is directed at the cause of PH 
• The goals of pharmacotherapy are to reduce mortality and 
morbidity, and prevent complications associated with acute 
bleeding related to PH 
• Pharmacologic therapy for PH includes the use of vasoconstrictors 
and vasodilators 
• Beta-blockers are used to provide primary and secondary 
prophylaxis 
• The vasoconstrictors somatostatin and octreotide are used to 
treat acute bleeding in patients with PH before performing 
endoscopy 
• Vasodilators such as isosorbide mononitrate reduce intrahepatic 
vascular resistance without decreasing peripheral or portal-
collateral resistance 
 
http://emedicine.medscape.com/article/182098-medication?src=refgatesrc1 
TREATMENT 
There are three aims or problems requiring 
treatment by surgical procedure:  
• Esophageal varices and variceal bleeding  
• Splenomegaly with hypersplenism  
• Ascites  
Among these conditions, treatment of 
bleeding, esophageal varices is the most 
important aspect of the therapy of portal 
hypertension 
https://www.slideshare.net/deepak15/portal-hypertension12-
presentation 
TREATMENT 
Esophageal varices: Pharmacologic therapy 
https://www.aasld.org/sites/default/files/Garcia-Tsao_et_al-2017-Hepatology.pdf 
TREATMENT 
Esophageal varices: Pharmacologic therapy 
https://www.aasld.org/sites/default/files/Garcia-Tsao_et_al-2017-
Hepatology.pdf 
The immediate goal of therapy in these patients is to control bleeding, to prevent early 
recurrence (within 5 days) and prevent 6-week mortality, which is considered, by consensus, 
the main treatment outcome 
TREATMENT 
Esophageal varices: Endoscopic therapy 
● Endoscopic therapy is with sclerotherapy, banding ligation or a 
combination of both 
● Endoscopic treatment of varices gained acceptance in the 1970s with 
the advent of flexible endoscopy 
● In the 1990s endoscopic banding was introduced and has largely 
replaced sclerotherapy 
● Obliteration of varices with either technique requires several sessions, 
but studies suggest that banding requires less sessions, has a lower 
complication rate and that the rebleeding rate at two years is 30% to 
35% and is significantly lower with banding 
● Mortality is not significantly different between sclerotherapy and 
banding 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
TREATMENT 
Esophageal varices: Decompression 
● Radiologic shunt is by a transjugular intrahepatic portal systemic shunt 
(TIPS) and has become a popular method to treat variceal bleeding in 
the 1990s, especially in the acute setting 
● TIPS are introduced through the right internal jugular vein, 
catheterization of a main hepatic vein, transparenchymal 
catheterization of the portal vein, and serial dilation of the track until 
large enough to insert a stent. Once placed the stent is dilated 
sufficiently to reduce the portal systemic gradient below 12 mmHg 
● Absolute contraindications to placement are rightsided heart failure, 
severe liver failure and polycystic liver disease. Relative 
contraindications such as hepatic tumors, encephalopathy and hepatic 
or portal vein thrombosis are judged individually. Complications of TIPS 
include acute stent thrombosis, hemobilia, stent migration and others 
related to angiography in general https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
TREATMENT 
Hepatorenal Syndrome 
 • Use of renal vasodilators (dopamine and prostaglandin 
analogues) was abandoned due to side effects and lack of 
adequate data confirming the benefits 
• In most studies, vasoconstrictors were given in combination with 
albumin, with improved efficacy 
• Administration of terlipressin (0.5 2 mg/4–6h intravenously) is 
associated with an improvement in renal function in about 60% of 
the patients and the incidence of ischaemic side-effects is about 
10% 
•  Somatostatin analogues (octreotide), and alpha-adrenergic 
agonists (midodrine and noradrenaline) have also been used 
• Midodrine (7.5–12.5 mg/8 hr orally) is found to be effective and is 
often used as a first-line treatment since the cost of terlipressin is 
high and it may not be available in some countries 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
TREATMENT 
HE 
• Identify the precipitating factors 
• Stop diuretics 
• Empty bowels of nitrogen containing content 
– Control bleeding 
– Protein­free diet 
• Lactulose (β-galactosidofructose) and lactitol (β-
galactosidosorbitol)  
• Antibiotics: rifaximin; other: neomycin (an aminoglycoside), 
metronidazole (for anaerobes only), paromomycin, and oral 
vancomycin 
• Maintain energy, fluid, and electrolyte balance 
• Increase dietary protein slowly with recovery 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–
89. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127024/ 
TREATMENT 
Liver transplantation  
 
• Liver transplantation has changed the management of PH in the 
1990s 
• The occurrence of ascites and encephalopathy with variceal 
bleeding may indicate advanced liver disease and if the patient has 
no contraindications, liver transplantation may be indicated 
• However, if the patient has adequate liver function, treatment 
should be directed at the variceal bleeding: liver transplantation is 
reserved for patients with end stage liver disease 
• Shortage of donor organs dictates that recipients may wait for 
transplantation for an extended period of time 
• During this period, patients with portal hypertension and variceal 
bleeding may need treatment that bridges them to 
transplantation such as endoscopic therapy or TIPS 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904420/ 
TREATMENT 
Ascites 
1.Dietary sodium restriction: two grams (88 
mmol) of sodium per day is appropriate for 
most patients 
2.Fluid restriction is not needed unless the 
patient has hyponatremia 
3.Diuretic therapy: spironolactone is the drug 
of choice, 100 mg - starting dose; furosemide, 
starting dose 40 mg 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–
89. 
Therapeutic Paracentesis 
• Hemodynamic changes, hyponatremia, and 
azotemia may occur after removal of 4 L to 
15 L of fluid, requiring administration of a 
plasma expander, usually albumin 
• Albumin, 6 g to 8 g, should be given per liter 
of fluid removed for paracentesis greater 
than 5 L 
 
TREATMENT 
Ascites 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–
89. 
TREATMENT 
Ascites 
Monitoring 
• Twice weekly, renal function and serum 
electrolytes should be monitored during dose 
adjustment 
• Target weight loss should be 1 kg to 2 kg a 
day if peripheral edema is present but only 
0.5 kg a day in patients without edema 
 
 
Yong E. Ascites: Tapping into the Problem / E. Yong, M. Cooper. // The Canadian Journal of Diagnosis. – March, 2003. – С. 81–
89. 
THE END 
